Roth Capital Estimates Accuray’s Q1 Earnings (NASDAQ:ARAY)

Accuray Incorporated (NASDAQ:ARAY) – Equities research analysts at Roth Capital issued their Q1 2027 earnings per share (EPS) estimates for Accuray in a research note issued to investors on Wednesday, August 13th. Roth Capital analyst J. Wittes anticipates that the medical equipment provider will post earnings of ($0.02) per share for the quarter. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q2 2027 earnings at ($0.01) EPS, Q3 2027 earnings at $0.01 EPS and Q4 2027 earnings at $0.03 EPS.

Accuray (NASDAQ:ARAY) last released its earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $127.54 million for the quarter, compared to analyst estimates of $123.78 million. Accuray had a negative return on equity of 5.79% and a negative net margin of 0.35%.

A number of other equities analysts have also recently weighed in on the company. Wall Street Zen cut Accuray from a “buy” rating to a “hold” rating in a research note on Saturday. BTIG Research reissued a “buy” rating and issued a $5.00 price target (up previously from $4.00) on shares of Accuray in a research note on Thursday.

Accuray Price Performance

NASDAQ:ARAY opened at $1.40 on Friday. The business’s 50-day moving average price is $1.34 and its 200 day moving average price is $1.62. The firm has a market cap of $157.70 million, a P/E ratio of -70.00 and a beta of 1.24. Accuray has a 52-week low of $1.14 and a 52-week high of $2.95. The company has a quick ratio of 0.92, a current ratio of 1.64 and a debt-to-equity ratio of 3.35.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Gabelli Funds LLC raised its stake in shares of Accuray by 12.5% in the 4th quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock valued at $89,000 after acquiring an additional 5,000 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Accuray by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider’s stock valued at $4,329,000 after acquiring an additional 6,758 shares in the last quarter. Northern Trust Corp raised its stake in shares of Accuray by 0.9% in the 4th quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider’s stock valued at $1,603,000 after acquiring an additional 7,399 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Accuray by 50.7% in the 4th quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 9,187 shares in the last quarter. Finally, North Star Investment Management Corp. increased its position in Accuray by 1.0% in the 1st quarter. North Star Investment Management Corp. now owns 1,058,545 shares of the medical equipment provider’s stock worth $1,895,000 after buying an additional 10,000 shares during the period. 64.08% of the stock is owned by institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.